Media Pack|Subscribe|E-Newsletter
|Admin
Biotechnology Media Insights Logo
RespiratoryMerck

Merck Reports Phase 3 Results for Gefapixant in Refractory Chronic Cough

BMI

Biotechnology Media Insights

Editorial Team · July 28, 2025

Merck announces Phase 3 COUGH-1 and COUGH-2 trial results showing gefapixant significantly reduces cough frequency in patients with refractory or unexplained chronic cough.

Respiratory disease research with pharmaceutical drug development laboratory

Merck today announced results from the Phase 3 COUGH-1 and COUGH-2 trials evaluating gefapixant in patients with refractory or unexplained chronic cough. Both trials demonstrated significant reductions in 24-hour cough frequency compared to placebo at week 12.

BMI

Biotechnology Media Insights

Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.

← Previous

Pfizer Receives FDA Approval for Cibinqo in Adolescents with Atopic Dermatitis

Next →

Gilead Sciences Presents 96-Week Safety and Efficacy Data for Biktarvy in HIV Treatment

Biotechnology Media Insights — Pharma & Life Sciences News